Physician profile
Rachel S Eidelman
NPI 1518941012
$9,507.11
in general payments reported to CMS, 2019-2025
29 companies · $1,616 in 2025
The $1,616 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,323 · 2020: $1,277 · 2021: $1,350 · 2022: $1,737 · 2023: $1,133 · 2024: $1,072 · 2025: $1,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,820.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,188.31 | 2019-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $1,142.16 | 2019-2024 | Xarelto |
| Amgen INC. | $1,027.40 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $657.26 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $610.94 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $582.99 | 2019-2025 | Farapulse, Watchman Flx, Bodyguardian |
| Esperion Therapeutics, INC. | $557.00 | 2020-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $530.63 | 2021-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $507.53 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $501.54 | 2019-2025 | Amplatzer Amulet |
| Sanofi-Aventis U.S. LLC | $318.83 | 2019-2024 | |
| Novo Nordisk INC | $303.89 | 2021-2025 | Wegovy, Ozempic |
| Cvrx, INC. | $282.59 | 2020-2025 | Barostim Neo System |
| Pfizer INC. | $262.24 | 2019-2024 | |
| Amarin Pharma, INC. | $259.04 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $130.33 | 2023-2025 | |
| Heartflow, INC. | $122.75 | 2022 | |
| Medtronic, INC. | $94.39 | 2022-2024 | Micra |
| Philips North America LLC | $90.56 | 2022 | |
| Lilly USA, LLC | $79.47 | 2024-2025 | Mounjaro, Zepbound |
| Kowa Pharmaceuticals America, INC. | $39.32 | 2019 | |
| Atricure, INC. | $32.04 | 2023 | |
| Biosense Webster, INC. | $30.29 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $29.71 | 2024 | Arcalyst |
| Lundbeck LLC | $29.70 | 2019 | |
| Braemar Manufacturing, LLC | $28.53 | 2019 | |
| Astellas Pharma US INC | $26.58 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $23.17 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Eidelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.